## **CASCINATION**

Quality


# Nore patients Better results

Quality Ablation with CAS-One® IR Driven by Al




1

Reproducible and standardized ablations for liver, kidney, lung, musculoskeletal, pancreas, and beyond.<sup>1,2</sup>



**CASCINATION** 



CASCINATION

Now with Al-driven features including: Automatic organ segmentation including risk structures A more accurate AblaSure<sup>®</sup> algorithm Interactive planning mode

## **Clinical benefits** More patients, better results

## **Economic benefits** Volume growth, cost savings



### Enhanced reliability and accuracy with CT/MRI planning and navigation

- Plan and navigate treatment intuitively in 2D and 3D
- Treat invisible lesions through MRI fusion<sup>3</sup>
- Visualise ablation volumes of >75 MWA, RFA, Cryo, IRE devices<sup>4</sup>
- Improve accuracy through mechanical needle guidance<sup>5,6</sup>
- Achieve low repositioning rates (1%)<sup>7</sup>

### Extensive treatment capabilities for challenging tumour cases

- Easier treatment of complex cases with high angulation/long trajectory<sup>8</sup>
- Low instrument repositioning rate (1%)<sup>7</sup>
- Place instruments in proximity to structures of risk
- Treat multiple/large tumours (>3 cm) with overlapping ablation volumes<sup>8,9</sup>



#### Reduced complications and recurrence rates

- Significantly reduce recurrence rates (9% vs 14–30%)<sup>1</sup>
- Low overall complication rates (6%)<sup>8</sup>
- Add consistency to treatment success with ablation confirmation<sup>10</sup>
- Reduce bleeding/seeding through low needle repositioning rate (1%)<sup>7</sup>

### Potential volume growth by increasing

- Efficiency in interventional treatments
- Ablation treatments that are now feasible through Quality Ablation
- Treatments through other modalities in other departments
- CT diagnostic capacity through standardisation


### Potential cost savings through reducing


- Re-ablations due to reduced recurrence
- Re-biopsies due to "first attempt" success
- Complications

- Radiation exposure

 Quantity of ablation needles needed through diligent planning Time from leading radiologist with standardisation Costly treatments (surgery, chemotherapy)

## **Quality Ablation**






## AblaSure® Add certainty through quantitative margin assessment

#### Ablation margins

- Objective assessment is key for quality outcomes
- Visual inspection might misjudge by up to 44%<sup>10,11</sup>


#### AblaSure provides for

- Automatic measurement of effective ablation volume
- Immediate 3D assessment of effective vs planned volume
- **Objective** statistical assessment of effective margins






000 00.



CASCINATION

## Maximize Quality Ablation Performance and potential



Extended warranty and access to a loaner pool. Minimised downtime and increased productivity.

#### Software excellence

Instant access to the latest features, updates and instrument data base. Ensure maximum utilisation.

### Clinical excellence

Guaranteed case support. Premium training and education offerings for optimal team performance.

## **Clinical evidence** Publications and cases

Since its launch in 2013 an increasing body of evidence supports percutaneous tumour treatment with CAS-One IR.

A comprehensive list of publications can be found online.

Monthly selected "Top Cases" feature challenging cases and how CAS-One IR made a difference.

Read our publications



nann, M., et al.: 1000 consecutive ablation sessions in the era of computer assisted image guidance, Euro J Rad O 2018 eit, N.: Stereotactic percutaneous RFA of Osteoid Osteomas using 3d-CT-Guidance, CIRSE 2020 mas et al.: Value of MRI/CT Image Fusion for Targeting invisible Lesions Cardiovasc Intervent Radiol 2020 ng of liver lesions. Int J Med Robot. 2014

an, P, et al.; Safety and efficacy of stereotactic radiofrequency ablation for very large ( $\geq$ 8 m) primary and met et al.: Minimal ablative margin (MAM) ass ment with image fusion Eur Radiol. 2020 Laimer et al.; Can accurate treatment success after RFA in liver be achieved by visual inspection alone? Inernational Journal of Hyperthermia 2020



Read our Top Cases Blog



CASCINATION AG Steigerhubelstrasse 3 CH-3008 Bern

Phone +41 31 306 26 26 info@cascination.com www.cascination.com



# CASC18-1264090756-36 EN